# Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions

> **NCT07654283** · PHASE2 · RECRUITING · sponsor: **AusperBio Therapeutics Inc.** · enrollment: 70 (estimated)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** AHB-137

## Key facts

- **NCT ID:** NCT07654283
- **Lead sponsor:** AusperBio Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2027-05-11
- **Final completion:** 2028-07-26
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07654283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07654283, "Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07654283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*